Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2014

Open Access 01-12-2014 | Research article

Effects of differences in serum total homocysteine, folate, and vitamin B12on cognitive impairment in stroke patients

Authors: Bo Jiang, Yumei Chen, Guoen Yao, Cunshan Yao, Hongmei Zhao, Xiangdong Jia, Yunyan Zhang, Junling Ge, Enchao Qiu, Chengyun Ding

Published in: BMC Neurology | Issue 1/2014

Login to get access

Abstract

Background

Vascular cognitive impairment-no dementia (VCIND) refers to the early or mild cognitive impairment induced by cerebral vascular injury. Research shows that serum total homocysteine (tHcy) level is an independent risk factor for cerebral vascular disease and may be closely related to cognitive function.Current studies on the tHcy level in VCIND patients are limited, and the relationship of tHcy with cognitive function remains unclear. This study aims to investigate the tHcy levels in patients with VCIND and to determine their correlation with cognitive function, as well as to provide useful clues for preventing and treating VCIND.

Methods

The tHcy, folate, and vitamin B12 levels in 82 patients with VCIND were reviewed retrospectively and compared with those of 80 stroke patients without cognitive impairment and 69 healthy controls by using the Montreal Cognitive Assessment (MoCA) scale and the event-related potential P300 to evaluate cognitive function.

Results

The tHcy levels in the VCIND group were higher than those in the other two groups, whereas the folate and Vitamin B12 levels in the VCIND group were lower than those of the other two groups. The tHcy levels in the stroke group were higher than those in the control group, and the folate and vitamin B12 levels in the stroke group were lower than those in the control group. The patients in the VCIND group with high tHcy exhibited lower MoCA scores and prolonged P300 latency than those in with normal tHcy. Correlation analysis showed that tHcy level is positively correlated with P300 latency period and negatively correlated with MoCA score.

Conclusion

The tHcy levels were significantly higher and the vitamin B12 and folate levels were significantly lower in the patients with VCIND than those in the other groups. The high tHcy levels in the VCIND patients may be correlated with impaired cognitive function.
Literature
1.
Moorhouse P, Rockwood K: Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 2008, 7: 246-255. 10.1016/S1474-4422(08)70040-1.CrossRefPubMed
2.
Serrano S, Domingo J, Rodríguez-Garcia E, Castro MD, del Ser T: Frequency of cognitive impairment without dementia in patients with stroke: a two-year follow-up study. Stroke. 2007, 38: 105-110. 10.1161/01.STR.0000251804.13102.c0.CrossRefPubMed
3.
Stephan BC, Matthews FE, Khaw KT, Dufouil C, Brayne C: Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Ther. 2009, 1: 4-10.1186/alzrt4.CrossRefPubMedPubMedCentral
4.
Manolescu BN, Oprea E, Farcasanu IC, Berteanu M, Cercasov C: Homocysteine and vitamin therapy in stroke prevention and treatment: a review. Acta Biochim Pol. 2010, 57: 467-477.PubMed
5.
Sala I, Belén Sánchez-Saudinós M, Molina-Porcel L, Lázaro E, Gich I, Clarimón J, Blanco-Vaca F, Blesa R, Gómez-Isla T, Lleó A: Homocysteine and cognitive impairment. relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord. 2008, 26: 506-512. 10.1159/000173710.CrossRefPubMed
6.
Román GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, López-Pousa S, Arizaga R, Wallin A: Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci. 2004, 226: 81-87. 10.1016/j.jns.2004.09.016.CrossRefPubMed
7.
Rockwood K, Howard K, MacKnight C, Darvesh S: Spectrum of disease in Vascular cognitive impairment. Neuroepidemiology. 1999, 18: 248-254. 10.1159/000026219.CrossRefPubMed
8.
Olsen TS, Langhorne P, Diener HC, Hennerici M, Ferro J, Sivenius J, Wahlgren NG, Bath P, European Stroke Initiative Executive Committee; EUSI Writing Committee: European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis. 2003, 16: 311-337. 10.1159/000072554.CrossRefPubMed
9.
Karunaratne S, Hanwella R, de Silva V: Validation of the sinhala version of the montreal cognitive assessment in screening for dementia. Ceylon Med J. 2011, 56: 147-153. 10.4038/cmj.v56i4.3892.CrossRefPubMed
10.
Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004, 50: 3-32. 10.1373/clinchem.2003.021634.CrossRefPubMed
11.
Herrmann W, Obeid R: Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med. 2011, 49: 435-441.PubMed
12.
Ford AH, Flicker L, Singh U, Hirani V, Almeida OP: Homocysteine, depression and cognitive function in older adults. J Affect Disord. 2013, 151: 646-651. 10.1016/j.jad.2013.07.012.CrossRefPubMed
13.
Budge M, Johnston C, Hogervorst E, de Jager C, Milwain E, Iversen SD, Barnetson L, King E, Smith AD: Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci. 2000, 903: 407-410. 10.1111/j.1749-6632.2000.tb06392.x.CrossRefPubMed
14.
Ashjazadeh N, Fathi M, Shariat A: Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci. 2013, 38: 233-239.PubMedPubMedCentral
15.
McNulty H, Strain JJ, Pentieva K, Ward M: C(1) metabolism and CVD outcomes in older adults. Proc Nutr Soc. 2012, 71: 213-221. 10.1017/S0029665111003387.CrossRefPubMed
16.
Kim G, Kim H, Kim KN, Son JI, Kim SY, Tamura T, Chang N: Relationship of cognitive function with B vitamin status, homocysteine, and tissue factor pathway inhibitor in cognitively impaired elderly: a cross-sectional survey. J Alzheimers Dis. 2013, 33: 853-862.PubMed
17.
Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD: Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013, 110: 9523-9528. 10.1073/pnas.1301816110.CrossRefPubMedPubMedCentral
18.
Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, García-Garcia D, Clavero P, Samaranch L, Irurzun C, Matsubara JM, Irigoien J, Bescos E, Kulisevsky J, Pérez-Tur J, Obeso JA: Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009, 24: 1437-1444. 10.1002/mds.22522.CrossRefPubMed
19.
Bangen KJ, Beiser A, Delano-Wood L, Nation DA, Lamar M, Libon DJ, Bondi MW, Seshadri S, Wolf PA, Au R: APOE Genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis. 2013, 22: 1361-1369. 10.1016/j.jstrokecerebrovasdis.2013.03.013.CrossRefPubMed
20.
Folin M, Baiguera S, Gallucci M, Conconi MT, Di Liddo R, Zanardo A, Parnigotto PP: A cross-sectional study of homocysteine, NO-levels, and CT-findings in Alzheimer dementia, vascular dementia and controls. Biogerontology. 2005, 6: 255-260. 10.1007/s10522-005-2622-3.CrossRefPubMed
21.
Troen AM, Shea-Budgell M, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH: B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc Natl Acad Sci U S A. 2008, 105: 12474-12479. 10.1073/pnas.0805350105.CrossRefPubMedPubMedCentral
22.
Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Pratico D: Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2010, 7: 140-149. 10.2174/156720510790691326.CrossRefPubMedPubMedCentral
23.
McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM: A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006, 354: 2764-2772. 10.1056/NEJMoa054025.CrossRefPubMed
24.
Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC: Plasma abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology. 2009, 72: 268-272. 10.1212/01.wnl.0000339486.63862.db.CrossRefPubMedPubMedCentral
25.
Abla D, Katahira K, Okanoya K: On-line assessment of statistical learning by event-related potentials. J Cogn Neurosci. 2008, 20: 952-964. 10.1162/jocn.2008.20058.CrossRefPubMed
26.
27.
Medvidovic S, Titlic M, Maras-Simunic M: P300 evoked potential in patients with mild cognitive impairment. Acta Inform Med. 2013, 21: 89-92. 10.5455/aim.2013.21.89-92.CrossRefPubMedPubMedCentral
28.
Braverman ER, Chen TJ, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K: Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 2007, 29: 55-67. 10.1007/s11357-007-9030-3.CrossRef
29.
Park EJ, Han SI, Jeon YW: Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2010, 34: 674-680. 10.1016/j.pnpbp.2010.03.011.CrossRefPubMed
Metadata
Title
Effects of differences in serum total homocysteine, folate, and vitamin B12on cognitive impairment in stroke patients
Authors
Bo Jiang
Yumei Chen
Guoen Yao
Cunshan Yao
Hongmei Zhao
Xiangdong Jia
Yunyan Zhang
Junling Ge
Enchao Qiu
Chengyun Ding
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2014
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-014-0217-9

Other articles of this Issue 1/2014

BMC Neurology 1/2014 Go to the issue

Research article

Young individuals with stroke: a cross sectional study of long-term disability associated with self-rated global health

Case report

Reversible Pisa syndrome associated to subdural haematoma: case-report

Research article

The efficacy and safety of cilostazol for the secondary prevention of ischemic stroke in acute and chronic phases in Asian population- an updated meta-analysis

Research article

Prediction of recurrent stroke with ABCD2 and ABCD3 scores in patients with symptomatic 50-99% carotid stenosis

Research article

Interactions between cognitive and sensory load while planning and controlling complex gait adaptations in Parkinson’s disease

Research article

Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia